-
hcup-us.ahrq.gov/db/nation/nis/tools/stats/FileSpecifications_NIS_2004_10PCT_SAMPLE_B.TXT
January 01, 2004 - as received from source)
NIS 2004 10Pct_Sample_B 74 PAY2 310 311 Num Secondary … expected payer (uniform)
NIS 2004 10Pct_Sample_B 75 PAY2_X 312 321 Char Secondary
-
hcup-us.ahrq.gov/db/nation/nis/tools/stats/FileSpecifications_NIS_2006_Core.TXT
January 01, 2006 - as received from source)
NIS 2006 Core 76 PAY2 314 315 Num Secondary … expected payer (uniform)
NIS 2006 Core 77 PAY2_X 316 325 Char Secondary
-
hcup-us.ahrq.gov/db/nation/nis/tools/stats/FileSpecifications_NIS_2003_CORE.TXT
January 01, 2003 - as received from source)
NIS 2003 CORE 74 PAY2 309 310 Num Secondary … expected payer (uniform)
NIS 2003 CORE 75 PAY2_X 311 320 Char Secondary
-
hcup-us.ahrq.gov/reports/statbriefs/sb162.pdf
March 01, 2013 - Secondary diagnoses are concomitant conditions that coexist at the time of
admission or develop during
-
hcup-us.ahrq.gov/reports/statbriefs/sb123.jsp
November 01, 2011 - Secondary diagnoses are concomitant conditions that coexist at the time of admission or that develop
-
hcup-us.ahrq.gov/reports/statbriefs/sb104.jsp
January 01, 2011 - Secondary diagnoses are concomitant conditions that coexist at the time of admission or that develop
-
hcup-us.ahrq.gov/reports/statbriefs/sb103.jsp
December 01, 2010 - Secondary diagnoses are concomitant conditions that coexist at the time of admission or that develop
-
digital.ahrq.gov/sites/default/files/docs/artificial-intelligence-tools-improve-slides-03182025.pdf
March 18, 2025 - recognize who was in
the intervention group.
52
Ongoing work
• Time to proactive clinical action
• Secondary
-
hcup-us.ahrq.gov/reports/statbriefs/sb180-Hospitalizations-United-States-2012.pdf
January 01, 2012 - Secondary diagnoses are concomitant conditions that coexist at the time of
admission or develop during
-
hcup-us.ahrq.gov/db/nation/nis/APS-DRGs-Weights_Public_v24.pdf
March 01, 2008 - derived from the patient’s CMS DRG and the severity
class is obtained by evaluating the patient’s secondary
-
digital.ahrq.gov/sites/default/files/docs/reducing-provider-burden-slides-012518.pdf
January 25, 2018 - Visit process data
Body
tracking
Eyetracking
Primary Instruments Secondary
-
www.ahrq.gov/patient-safety/reports/liability/etchegaray.html
August 01, 2017 - significant differences existed between those in the baseline dataset and follow-up dataset to address our secondary
-
www.ahrq.gov/sites/default/files/wysiwyg/patient-safety/resources/simulation/simulation-issue-brief.pdf
July 01, 2024 - ■ Optimize the direct and secondary benefits, such as designing and implementing simulations that
-
hcup-us.ahrq.gov/db/nation/nis/tools/stats/MaskedStats_NIS_2017_Core.PDF
January 01, 2017 - MYELOPROLIF DIS OR POORLY DIFF NEOPL DIAG W/O CC/MCC 312 0.00%
846: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY … DIAGNOSIS W MCC 3,646 0.05%
847: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS W CC 17,281 … 0.24%
848: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS W/O CC/MCC 839 0.01%
849: RADIOTHERAPY
-
hcup-us.ahrq.gov/db/nation/nis/tools/stats/MaskedStats_NIS_2016_Core.PDF
January 01, 2016 - MYELOPROLIF DIS OR POORLY DIFF NEOPL DIAG W/O CC/MCC 346 0.00%
846: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY … DIAGNOSIS W MCC 3,257 0.05%
847: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS W CC 17,564 … 0.25%
848: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS W/O CC/MCC 1,006 0.01%
849: RADIOTHERAPY
-
www.uspreventiveservicestaskforce.org/home/getfilebytoken/7ZSKduUYHWKe7q_tTY9xbF
April 01, 2013 - trials that were designed and powered to demon-
strate invasive breast cancer incidence as a primary or
secondary … For raloxifene, breast cancer inci-
dence was a primary outcome in RUTH and a secondary
outcome in MORE … for 1 variable; another varies by using categorical rather than ordinal variables.
� Developed using secondary
-
hcup-us.ahrq.gov/db/nation/nrd/stats/MaskedStats_NRD_2017_Core.PDF
January 01, 2017 - MYELOPROLIF DIS OR POORLY DIFF NEOPL DIAG W/O CC/MCC 833 0.00%
846: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY … DIAGNOSIS
W MCC
9,228 0.05%
847: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS
W CC
43,151 … 0.24%
848: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS
W/O CC/MCC
1,976 0.01%
849: RADIOTHERAPY
-
www.uspreventiveservicestaskforce.org/uspstf/recommendation/obesity-in-adults-screening-and-counseling-2003
November 03, 2003 - improved self-esteem in both treatment groups. 38 The USPSTF found mixed evidence of improvements of secondary
-
digital.ahrq.gov/sites/default/files/docs/citation/r21hs023849-valdez-final-report-2018.pdf
January 01, 2018 - A
secondary analysis further provided recommendations on how informatics designers and
professionals
-
psnet.ahrq.gov/perspective/resilient-healthcare-and-safety-i-and-safety-ii-frameworks
December 14, 2022 - That secondary affective lesson in simulation is very relevant for clinical care.